Mostrar el registro sencillo del ítem

Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder

dc.creatorHernández, María Eugenia
dc.creatorMendieta, Danelia
dc.creatorMartínez-Fong, Daniel
dc.creatorLoría, Frida
dc.creatorMoreno, Julia
dc.creatorEstrada, Iris
dc.creatorBojalil, Rafael
dc.creatorPavón, Lenin
dc.date.accessioned2017-06-29T06:02:50Z
dc.date.available2017-06-29T06:02:50Z
dc.date.issued2008es_ES
dc.identifier561es_ES
dc.identifier.issn0924-977Xes_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/5248
dc.identifier.urihttps://doi.org/10.1016/j.euroneuro.2008.08.001es_ES
dc.language.isoenges_ES
dc.relation18 (12) 917-924 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.subject.meshAdultes_ES
dc.subject.meshAnalysis of Variancees_ES
dc.subject.meshAntidepressive Agents-therapeutic usees_ES
dc.subject.meshCytokines-bloodes_ES
dc.subject.meshDepressive Disorder, Major-bloodes_ES
dc.subject.meshDepressive Disorder, Major-drug therapyes_ES
dc.subject.meshEnzyme-Linked Immunosorbent Assayes_ES
dc.subject.meshFemalees_ES
dc.subject.meshHumanses_ES
dc.subject.meshHydrocortisone-bloodes_ES
dc.subject.meshLongitudinal Studieses_ES
dc.subject.meshMalees_ES
dc.subject.meshPsychiatric Status Rating Scaleses_ES
dc.subject.meshRadioimmunoassay-methodses_ES
dc.subject.meshRetrospective Studieses_ES
dc.subject.meshSerotonin Uptake Inhibitors-therapeutic usees_ES
dc.subject.meshTime Factorses_ES
dc.subject.meshYoung Adultes_ES
dc.titleVariations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorderes_ES
dc.typearticlees_ES
dc.contributor.affiliationDepartment of Psychoimmunology, National Institute of Psychiatry "Ramón de la Fuente", México.es_ES
dc.relation.jnabreviadoEUR NEUROPSYCHOPHARMACOLes_ES
dc.relation.journalEuropean Neuropsychopharmacologyes_ES
dc.identifier.placeNetherlandses_ES
dc.date.published2008es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.eissn1873-7862es_ES
dc.identifier.doi10.1016/j.euroneuro.2008.08.001es_ES
dc.description.monthDices_ES
dc.description.abstractotrodiomaMajor depressive disorder (MDD) is a psychiatric condition characterized by hypercortisolism and variations in circulatory cytokines. Previously it has been reported that administration of selective serotonin reuptake inhibitors (SSRI) in MDD patients modify cortisol and cytokine levels but these studies only evaluated changes over a short time period. This work reports the long-term effects of administration of SSRI on the cortisol levels and pro--anti-inflammatory cytokine profile in a group of MDD patients treated for 52 weeks. A total of 31 patients diagnosed with MDD received anti depressant treatment with SSRI. HDRS and BDI were administered over a year, and levels of interleukin IL-1beta, IL-10, IL-2, IFN-gamma, IL-4, IL-13, and 24-h urine cortisol were determined at weeks (W) 0, 5, 20, 36 and 52 of treatment. Before treatment we found high levels of cortisol, IL-4, IL-13 (Th2) and IL-10 in MDD patients when compared with healthy volunteers. At W20 psychiatric scales indicated a remission of the depressive episode concomitantly with increments in IL-2 and IL-1beta but without changes in cortisol. Towards the end of the treatment (W52) we observed a significant reduction (p<0.01) in cortisol levels, with an increment in IL-1beta and IFN-gamma and a decrease in Th2 cytokines. Our results suggest that depressed patients only reach a partial reestablishment of HPA axis function after the long-term administration of SSRI.es_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem